Sökning: WFRF:(Häggman Michael)
> Damber Jan Erik >
Open-label, clinica...
Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer.
-
- Bratt, Ola (författare)
- Lund University,Lunds universitet,Urologi,Forskargrupper vid Lunds universitet,Urology,Lund University Research Groups
-
- Häggman, Michael (författare)
- Uppsala universitet,Urologkirurgi
-
- Ahlgren, Göran (författare)
- Lund University,Lunds universitet,Institutionen för kliniska vetenskaper, Malmö,Medicinska fakulteten,Department of Clinical Sciences, Malmö,Faculty of Medicine
-
visa fler...
-
Nordle, O (författare)
-
Björk, A (författare)
-
- Damber, Jan-Erik, 1949 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
-
visa färre...
-
(creator_code:org_t)
- 2009-09-15
- 2009
- Engelska.
-
Ingår i: British journal of cancer. - : Springer Science and Business Media LLC. - 1532-1827 .- 0007-0920. ; 101:8, s. 1233-40
- Relaterad länk:
-
https://www.nature.c...
-
visa fler...
-
http://www.ncbi.nlm....
-
http://dx.doi.org/10...
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
https://lup.lub.lu.s...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND: Tasquinimod is a quinoline-3-carboxamide derivative with anti-angiogenic activity. Two open-label phase I clinical trials in patients were conducted to evaluate the safety and tolerability of tasquinimod, with additional pharmacokinetic and efficacy assessments. METHODS: Patients with castration-resistant prostate cancer with no previous chemotherapy were enrolled in this study. The patients received tasquinimod up to 1 year either at fixed doses of 0.5 or 1.0 mg per day or at an initial dose of 0.25 mg per day that escalated to 1.0 mg per day. RESULTS: A total of 32 patients were enrolled; 21 patients were maintained for >or=4 months. The maximum tolerated dose was determined to be 0.5 mg per day; but when using stepwise intra-patient dose escalation, a dose of 1.0 mg per day was well tolerated. The dose-limiting toxicity was sinus tachycardia and asymptomatic elevation in amylase. Common treatment-emergent adverse events included transient laboratory abnormalities, anaemia, nausea, fatigue, myalgia and pain. A serum prostate-specific antigen (PSA) decline of >or=50% was noted in two patients. The median time to PSA progression (>25%) was 19 weeks. Only 3 out of 15 patients (median time on study: 34 weeks) developed new bone lesions. CONCLUSION: Long-term continuous oral administration of tasquinimod seems to be safe, and the overall efficacy results indicate that tasquinimod might delay disease progression.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Aged
- Aged
- 80 and over
- Angiogenesis Inhibitors
- therapeutic use
- Humans
- Male
- Maximum Tolerated Dose
- Middle Aged
- Orchiectomy
- Prostatic Neoplasms
- drug therapy
- Quinolines
- adverse effects
- pharmacokinetics
- therapeutic use
- Urology and andrology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas